ZOLADEX
Total Payments
$280,536
Transactions
3,108
Doctors
1,597
Companies
2
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2020 | $12,641 | 127 | 96 |
| 2019 | $63,884 | 1,253 | 649 |
| 2018 | $67,703 | 1,003 | 724 |
| 2017 | $136,308 | 725 | 561 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $216,252 | 57 | 77.1% |
| Food and Beverage | $57,813 | 3,024 | 20.6% |
| Travel and Lodging | $5,749 | 24 | 2.0% |
| Unspecified | $638.10 | 2 | 0.2% |
| Education | $84.00 | 1 | 0.0% |
Payments by Type
General
$279,898
3,106 transactions
Research
$638.10
2 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| Phase II trial of androgen deprivation therapy (ADT) and pembrolizumab for advanced stage androgen receptor-positive salivary gland carcinoma: Big Ten Cancer Research Consortium | TerSera Therapeutics LLC | $638.10 | 0 |
Top Doctors Receiving Payments for ZOLADEX
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Joseph Bailes | — | Frisco, TX | $87,696 | 30 |
| , MD | Urology | Niles, IL | $82,000 | 9 |
| , MD | Hematology & Oncology | Rochester, MN | $7,050 | 5 |
| , M.D | Medical Oncology | Fort Myers, FL | $4,298 | 8 |
| , M.D., PH.D | Internal Medicine | Los Angeles, CA | $3,496 | 1 |
| , MD | Internal Medicine | Stanford, CA | $3,442 | 6 |
| , MD | Medical Oncology | Columbus, OH | $3,160 | 7 |
| , M.D | Medical Oncology | New York, NY | $3,138 | 6 |
| , MD | Medical Oncology | Durham, NC | $3,024 | 5 |
| Cheryl Harth | — | Dallas, TX | $2,833 | 5 |
| , DR | Urology | Myrtle Beach, SC | $2,660 | 1 |
| , MD | Medical Oncology | Evanston, IL | $2,636 | 4 |
| , MD | Hematology & Oncology | Harvey, IL | $2,636 | 4 |
| , MD | Hematology & Oncology | Voorhees, NJ | $2,622 | 1 |
| , MD | Hematology | Fort Myers, FL | $1,182 | 7 |
| , MD | Hematology | Franklin, TN | $1,162 | 3 |
| , MD | Medical Oncology | Nashville, TN | $1,150 | 2 |
| , M.D | Medical Oncology | Murfreesboro, TN | $1,150 | 2 |
| , MD | Medical Oncology | Nashville, TN | $1,150 | 2 |
| , M.D | Medical Oncology | Fort Myers, FL | $1,135 | 3 |
| , M.D | Medical Oncology | Arlington, TX | $1,093 | 2 |
| , MD | Emergency Medicine | San Antonio, TX | $1,093 | 2 |
| , M.D | Emergency Medicine | Mesquite, TX | $1,093 | 2 |
| John Pippen | — | Dallas, TX | $1,093 | 2 |
| , MD | Medical Oncology | Dallas, TX | $1,093 | 2 |
Ad
Manufacturing Companies
- TerSera Therapeutics LLC $277,876
- AstraZeneca UK Limited $2,660
Product Information
- Type Drug
- Total Payments $280,536
- Total Doctors 1,597
- Transactions 3,108
About ZOLADEX
ZOLADEX is a drug associated with $280,536 in payments to 1,597 healthcare providers, recorded across 3,108 transactions in the CMS Open Payments database. The primary manufacturer is TerSera Therapeutics LLC.
Payment data is available from 2017 to 2020. In 2020, $12,641 was paid across 127 transactions to 96 doctors.
The most common payment nature for ZOLADEX is "Consulting Fee" ($216,252, 77.1% of total).
ZOLADEX is associated with 1 research study, including "Phase II trial of androgen deprivation therapy (ADT) and pembrolizumab for advanced stage androgen receptor-positive salivary gland carcinoma: Big Ten Cancer Research Consortium" ($638.10).